CytRx (CYTR) announced that it has reached enrollment target of 132 patients in its Phase 2b clinical trial assessing lead product candidate aldoxorubicin in treatment-experienced patients with small cell lung cancer (SCLC). The primary endpoint is progression-free survival (PFS) at Month 24. Overall survival is a secondary endpoint. According to, the estimated study completion date is July 2017, but this needs revising since the completion should be September 2018 based on two-year PFS data. Results from a recent Phase 3 study in soft tissue sarcoma failed to demonstrate a significant difference in PFS between aldoxorubicin and investigator's choice of therapy.